Clinical–pharmacodynamic discordance in pemphigus

Abstract

The ADDRESS trial showed a disconnect between anti-desmoglein antibody titres and clinical disease activity. We discuss whether conventional ELISA titres adequately reflect pathogenic antibody activity and suggest that functional or epitope-resolved assays may provide complementary information in future studies of FcRn blockade.

Clinical–pharmacodynamic discordance in pemphigus: beyond conventional anti-desmoglein ELISA

Abstract

Keywords

Authors

Read around a topic while you study.

Source

At a glance